<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6491">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01012674</url>
  </required_header>
  <id_info>
    <org_study_id>DGD-44-049</org_study_id>
    <nct_id>NCT01012674</nct_id>
  </id_info>
  <brief_title>Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)</brief_title>
  <official_title>Evaluation of Dotarem-enhanced MRA Compared to Time-Of-Flight (TOF) MRA in the Diagnosis of Carotid and Vertebral Basilar Arterial Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guerbet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guerbet</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients
      suffering from carotid or vertebral arterial disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA)
      followed by a Dotarem enhanced MRA
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Technical Failure Rate</measure>
    <time_frame>2 - 28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rate of non-assessable arterial segments as measured by 3 independent readers in off-site evaluation of TOF-MRA and Dotarem-enhanced MRA (re-read DGD-44-061).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>2-42 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rate of true stenotic segments (i.e. with stenosis &gt;= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-061).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity</measure>
    <time_frame>2 - 42 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rate of true non-stenotic segments (i.e. without stenosis &gt;= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-061).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and Specificity at Patient Level and at Segment Level Excluding Non-assessable Segments</measure>
    <time_frame>2-42 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Predictive Values of Dotarem-enhanced MRA and TOF MRA At Patient Level and at Segment Level</measure>
    <time_frame>2 - 42 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter and Intra-readers Agreement at the Segment Level</measure>
    <time_frame>2 - 42 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of the Different Reasons for Technical Failure for Both MRA Procedures</measure>
    <time_frame>2 - 42 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Images of Both MRA Procedures</measure>
    <time_frame>2 - 42 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Diagnostic Confidence for Both MRA Procedures</measure>
    <time_frame>2 - 42 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Size of Stenoses for All Imaging Procedures (MRA and Gold Standard)</measure>
    <time_frame>2 - 42 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Examination</measure>
    <time_frame>2- 42 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of the Recommended Clinical Management</measure>
    <time_frame>2 - 42 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>0 - 42 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Sampling</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance at the Injection Site</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">211</enrollment>
  <condition>Cerebral Arterial Diseases</condition>
  <arm_group>
    <arm_group_label>Dotarem and TOF MRA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem enhanced MRA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dotarem</intervention_name>
    <description>Each subject will receive one injection of Dotarem 0.2ml/kg</description>
    <arm_group_label>Dotarem and TOF MRA</arm_group_label>
    <other_name>Gadoterate meglumine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TOF MRA</intervention_name>
    <description>Each subject will undergo a Time Of Flight Magnetic Resonance Angiography (TOF MRA)</description>
    <arm_group_label>Dotarem and TOF MRA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged more than 18 years

          -  Strongly suspected of having carotid or vertebral arterial disease

          -  Scheduled (or to be scheduled) to undergo computed tomography angiography (CTA)
             examination

        Exclusion Criteria:

          -  Known grade IV or V chronic kidney disease (GFR&lt;30 mL/min/1.73m²)

          -  Contraindication to MRI

          -  Acute renal dysfunction within the 6 months preceding Dotarem®-enhanced MRA
             examination
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre DESCHE, MD</last_name>
    <role>Study Director</role>
    <affiliation>Guerbet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guerbet LLC</name>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <zip>47403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>August 25, 2015</lastchanged_date>
  <firstreceived_date>November 12, 2009</firstreceived_date>
  <firstreceived_results_date>July 29, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>carotid or vertebral artery disease</keyword>
  <keyword>Contrast agent</keyword>
  <keyword>MRA</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cerebral Arterial Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gadoterate meglumine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient first visit: 28 Oct 2009. Last patient last visit: 12 Oct 2010. Location: radiology departments</recruitment_details>
      <pre_assignment_details>A total of 211 patients fulfilling the eligibility criteria were enrolled, of which 187 patients received Dotarem and completed the study. Twenty-four patients did not receive Dotarem and were discontinued prematurely.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TOF MRA Followed by Dotarem-enhanced MRA</title>
          <description>Each patient will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem-enhanced MRA.
Each patient will be scheduled to undergo CTA either before TOF MRA or after Dotarem-enhanced MRA. CTA will be used as standard of truth.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="211"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="187"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TOF MRA Followed by Dotarem-enhanced MRA</title>
          <description>Each patient will undergo a Time Of Flight (TOF) Magnetic Resonance Angiography (MRA) followed by a Dotarem-enhanced MRA.
Each patient will be scheduled to undergo CTA either before TOF MRA or after Dotarem-enhanced MRA. CTA will be used as standard of truth.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="211"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="110"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="101"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="62.8" spread="12.7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="105"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="106"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="68"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Argentina</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="44"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>South Africa</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Mexico</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Korea, Republic of</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="30"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Chile</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Technical Failure Rate</title>
        <description>Rate of non-assessable arterial segments as measured by 3 independent readers in off-site evaluation of TOF-MRA and Dotarem-enhanced MRA (re-read DGD-44-061).</description>
        <time_frame>2 - 28 days</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Dotarem-enhanced MRA</title>
            <description>Patients benefiting from an MRA after Dotarem IV administration</description>
          </group>
          <group group_id="O2">
            <title>TOF MRA</title>
            <description>Patients benefiting from an MRA with no contrast medium administration</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="187"/>
                  <measurement group_id="O2" value="187"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Number of arterial segments analyzed</title>
            <units>Number of arterial segments</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2518"/>
                  <measurement group_id="O2" value="2518"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Technical Failure Rate</title>
            <description>Rate of non-assessable arterial segments as measured by 3 independent readers in off-site evaluation of TOF-MRA and Dotarem-enhanced MRA (re-read DGD-44-061).</description>
            <units>percentage of arterial segments</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Reader 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.55" lower_limit="2.84" upper_limit="4.26"/>
                  <measurement group_id="O2" value="29.22" lower_limit="27.48" upper_limit="30.96"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.57" lower_limit="1.09" upper_limit="2.04"/>
                  <measurement group_id="O2" value="17.65" lower_limit="16.19" upper_limit="19.11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.68" lower_limit="1.19" upper_limit="2.17"/>
                  <measurement group_id="O2" value="23.07" lower_limit="21.46" upper_limit="24.68"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensitivity and Specificity at Patient Level and at Segment Level Excluding Non-assessable Segments</title>
        <time_frame>2-42 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive and Negative Predictive Values of Dotarem-enhanced MRA and TOF MRA At Patient Level and at Segment Level</title>
        <time_frame>2 - 42 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity</title>
        <description>Rate of true stenotic segments (i.e. with stenosis &gt;= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-061).</description>
        <time_frame>2-42 days</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Dotarem-enhanced MRA</title>
            <description>Patients benefiting from an MRA after Dotarem IV administration</description>
          </group>
          <group group_id="O2">
            <title>TOF MRA</title>
            <description>Patients benefiting from an MRA with no contrast medium administration</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="187"/>
                  <measurement group_id="O2" value="187"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Number of arterial segments analyzed</title>
            <units>Number of arterial segments</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2532"/>
                  <measurement group_id="O2" value="2532"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Sensitivity</title>
            <description>Rate of true stenotic segments (i.e. with stenosis &gt;= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-061).</description>
            <units>percentage of arterial segments</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Reader 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="70.65" lower_limit="61.35" upper_limit="79.96"/>
                  <measurement group_id="O2" value="65.22" lower_limit="55.48" upper_limit="74.95"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="69.57" lower_limit="60.16" upper_limit="78.97"/>
                  <measurement group_id="O2" value="73.91" lower_limit="64.94" upper_limit="82.89"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="75.00" lower_limit="66.15" upper_limit="83.85"/>
                  <measurement group_id="O2" value="66.30" lower_limit="56.65" upper_limit="75.96"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Specificity</title>
        <description>Rate of true non-stenotic segments (i.e. without stenosis &gt;= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-061).</description>
        <time_frame>2 - 42 days</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Dotarem-enhanced MRA</title>
            <description>Patients benefiting from an MRA after Dotarem IV administration</description>
          </group>
          <group group_id="O2">
            <title>TOF MRA</title>
            <description>Patients benefiting from an MRA with no contrast medium administration</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="187"/>
                  <measurement group_id="O2" value="187"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Number of arterial segments analyzed</title>
            <units>Number of arterial segments</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2532"/>
                  <measurement group_id="O2" value="2532"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Specificity</title>
            <description>Rate of true non-stenotic segments (i.e. without stenosis &gt;= 70%) of TOF and Dotarem-enhanced MRA evaluated by 3 independent off-site readers at the segment level, with CTA as standard of truth (re-read DGD-44-061).</description>
            <units>percentage of arterial segments</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Reader 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98.03" lower_limit="97.48" upper_limit="98.58"/>
                  <measurement group_id="O2" value="84.34" lower_limit="82.90" upper_limit="85.79"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98.40" lower_limit="97.90" upper_limit="98.90"/>
                  <measurement group_id="O2" value="89.51" lower_limit="88.29" upper_limit="90.72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Reader 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98.61" lower_limit="98.14" upper_limit="99.07"/>
                  <measurement group_id="O2" value="88.40" lower_limit="87.13" upper_limit="89.67"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inter and Intra-readers Agreement at the Segment Level</title>
        <time_frame>2 - 42 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of the Different Reasons for Technical Failure for Both MRA Procedures</title>
        <time_frame>2 - 42 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Images of Both MRA Procedures</title>
        <time_frame>2 - 42 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Level of Diagnostic Confidence for Both MRA Procedures</title>
        <time_frame>2 - 42 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Size of Stenoses for All Imaging Procedures (MRA and Gold Standard)</title>
        <time_frame>2 - 42 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Examination</title>
        <time_frame>2- 42 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rates of the Recommended Clinical Management</title>
        <time_frame>2 - 42 days</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <time_frame>0 - 42 days</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Sampling</title>
        <time_frame>24 hours</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tolerance at the Injection Site</title>
        <time_frame>24 hours</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected since the patient signing the patient consent form till the end of the last visits, maximum duration is 42 days.</time_frame>
      <desc>Adverse Events reported during the 24 hours following TOF, 24 hours following Dotarem-enhanced MRA and 24 hours following CTA and Adverse Events in discontinued patients without Dotarem administration are described. Participants at risk were subjects exposed to Dotarem administration.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dotarem-enhanced MRA</title>
          <description>Patients benefiting from an MRA after Dotarem IV administration</description>
        </group>
        <group group_id="E2">
          <title>TOF MRA</title>
          <description>Patients benefiting from an MRA with no contrast medium administration</description>
        </group>
        <group group_id="E3">
          <title>Computerized Tomography Angiography (CTA)</title>
          <description>Patients benefiting from CT angiography after the IV administration of an iodinated contrast medium</description>
        </group>
        <group group_id="E4">
          <title>Patients Discontinued Without Dotarem Administration</title>
          <description>Patients withdrawn from the study before Dotarem IV administration whatever the reason</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Pierre Desché, MD - VP Head of Development, Medical and Regulatory Affairs</name_or_title>
      <organization>Guerbet</organization>
      <phone>+33 1 45 91 50 00</phone>
      <email>pierre.desche@guerbet-group.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
